drugset / Trial / NCT06072482
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Timeline
- Start
- 2024-02-07
- Primary completion
- 2036-12-31
- Completion
- 2036-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avacopan | Small molecule | 30 mg | Oral |